Based on many years of mature VCT data and experience, upwards of 10% or more may be duplicate research subjects or professional research subjects or potential protocol violations in your clinical trial. The consequences of this can be disastrous and can result in a clinical trials failure to meet its primary or secondary endpoints. There may be increased adverse events by combining multiple investigational products. So much time and money are spent planning and executing well-designed clinical trials. Why leave these issues to chance? There is a cost effective and easy to implement solution with an excellent return on investment by using VCT.
VCT detects these professional research subjects and issues at the time of screening and continues to protections the entire duration of the trial.